Fibrinolysis inhibition among COVID-19 patients, as indicated by the plasmin–antiplasmin complex (PAP)/plasminogen activator inhibitor 2 (PAI-2) ratio, was higher in survivors than in nonsurvivors, and a high D-dimer level and complete lack of clot lysis was reported in critically ill patients [25,26]. This evidence concerns the gene PLG and COVID-19.